Published in Trends Pharmacol Sci on July 13, 2007
Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov (2010) 5.76
Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov (2012) 3.30
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A (2011) 1.98
A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci (2011) 1.93
Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A (2008) 1.85
Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes. Mol Pharmacol (2008) 1.78
Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol (2012) 1.73
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A (2009) 1.63
Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev (2011) 1.61
Discovery of regulators of receptor internalization with high-throughput flow cytometry. Mol Pharmacol (2012) 1.61
The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci (2011) 1.60
Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther (2008) 1.52
Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat Rev Drug Discov (2009) 1.45
New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. Br J Pharmacol (2013) 1.43
Crosstalk between GABAB and mGlu1a receptors reveals new insight into GPCR signal integration. EMBO J (2009) 1.32
CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Nat Chem Biol (2011) 1.27
The effect of protein kinase C and G protein-coupled receptor kinase inhibition on tolerance induced by mu-opioid agonists of different efficacy. J Pharmacol Exp Ther (2009) 1.27
Synaptic activity unmasks dopamine D2 receptor modulation of a specific class of layer V pyramidal neurons in prefrontal cortex. J Neurosci (2012) 1.25
Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des (2010) 1.24
Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo. J Neurosci (2010) 1.21
Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists. J Med Chem (2012) 1.19
Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther (2008) 1.15
Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology (2014) 1.11
β-Adrenergic receptor subtype signaling in heart: from bench to bedside. Acta Pharmacol Sin (2012) 1.10
Ligand-dependent conformations and dynamics of the serotonin 5-HT(2A) receptor determine its activation and membrane-driven oligomerization properties. PLoS Comput Biol (2012) 1.10
Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons. J Biol Chem (2013) 1.08
Label-Free Receptor Assays. Drug Discov Today Technol (2011) 1.07
The potential for selective pharmacological therapies through biased receptor signaling. BMC Pharmacol Toxicol (2012) 1.07
Targeting G protein coupled receptor-related pathways as emerging molecular therapies. Saudi Pharm J (2013) 1.06
Dopamine receptor signaling and current and future antipsychotic drugs. Handb Exp Pharmacol (2012) 1.04
DREADDs: novel tools for drug discovery and development. Drug Discov Today (2013) 1.03
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues. Bioorg Med Chem Lett (2011) 1.03
Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches. Behav Pharmacol (2011) 1.02
Developing chemical genetic approaches to explore G protein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL). Mol Pharmacol (2011) 1.00
Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists. J Med Chem (2011) 0.98
Mismatch negativity: translating the potential. Front Psychiatry (2013) 0.97
Cannabinoid CB1 receptor-dependent long-term depression in autaptic excitatory neurons. J Neurophysiol (2009) 0.97
Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor. Mol Pharmacol (2014) 0.96
The analgesic efficacy of fentanyl: relationship to tolerance and mu-opioid receptor regulation. Pharmacol Biochem Behav (2008) 0.94
Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44. Pharmacol Biochem Behav (2009) 0.93
Selective agonism in somatostatin receptor signaling and regulation. Mol Cell Endocrinol (2007) 0.90
Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs (2015) 0.90
Arresting serotonin. Proc Natl Acad Sci U S A (2008) 0.90
Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications. Br J Pharmacol (2014) 0.90
Functional selectivity of GPCR signaling in animals. Curr Opin Cell Biol (2013) 0.90
Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists. ACS Med Chem Lett (2012) 0.89
Biased agonism. F1000 Biol Rep (2009) 0.88
Ensemble of G protein-coupled receptor active states. Curr Med Chem (2012) 0.88
Genetic deletion of p90 ribosomal S6 kinase 2 alters patterns of 5-hydroxytryptamine 2A serotonin receptor functional selectivity. Mol Pharmacol (2009) 0.86
Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg (2010) 0.86
Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model. Neuropharmacology (2013) 0.86
Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development. Neuropharmacology (2013) 0.85
Ligand functional selectivity advances our understanding of drug mechanisms and drug discovery. Neuropsychopharmacology (2010) 0.85
Ligand-directed functional selectivity at the mu opioid receptor revealed by label-free integrative pharmacology on-target. PLoS One (2011) 0.85
Serotonin receptor activity is necessary for olfactory learning and memory in Drosophila melanogaster. Neuroscience (2011) 0.84
Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat (2015) 0.84
SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C. Neuropharmacology (2014) 0.83
Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proc Natl Acad Sci U S A (2014) 0.83
CB₂: therapeutic target-in-waiting. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.83
Label-free integrative pharmacology on-target of opioid ligands at the opioid receptor family. BMC Pharmacol Toxicol (2013) 0.82
Biased β2 -adrenoceptor signalling in heart failure: pathophysiology and drug discovery. Br J Pharmacol (2014) 0.82
Dopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role? J Pharmacol Exp Ther (2014) 0.82
Functional selectivity in GPCR heterocomplexes. Mini Rev Med Chem (2012) 0.81
Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias. ACS Chem Neurosci (2015) 0.81
Synthesis and Agonistic Activity at the GPR35 of 5,6-Dihydroxyindole-2-carboxylic Acid Analogues. ACS Med Chem Lett (2012) 0.81
Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists. Mol Endocrinol (2011) 0.80
Phenylpiperazine derivatives with selectivity for dopamine D3 receptors modulate cocaine self-administration in rats. Neuropharmacology (2012) 0.80
Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats. PLoS One (2015) 0.80
Tyrosine 308 is necessary for ligand-directed Gs protein-biased signaling of β2-adrenoceptor. J Biol Chem (2014) 0.80
Receptor conformations involved in dopamine D(2L) receptor functional selectivity induced by selected transmembrane-5 serine mutations. Mol Pharmacol (2012) 0.80
Aspirin metabolites are GPR35 agonists. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.80
Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics. ACS Chem Neurosci (2011) 0.80
Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor. ACS Chem Neurosci (2015) 0.80
NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders. Neuropsychopharmacology (2008) 0.78
Being mindful of seven-transmembrane receptor 'guests' when assessing agonist selectivity. Br J Pharmacol (2010) 0.78
PharmGKB summary: dopamine receptor D2. Pharmacogenet Genomics (2011) 0.78
Agonist and antagonist effects of aripiprazole on D₂-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic tone. Int J Neuropsychopharmacol (2014) 0.77
Investigation of D₂ receptor-agonist interactions using a combination of pharmacophore and receptor homology modeling. ChemMedChem (2012) 0.77
Serotonin 5-HT₂ receptor activation prevents allergic asthma in a mouse model. Am J Physiol Lung Cell Mol Physiol (2015) 0.76
The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist. Biochem J (2012) 0.76
Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists. J Med Chem (2016) 0.76
Systematic errors in detecting biased agonism: Analysis of current methods and development of a new model-free approach. Sci Rep (2017) 0.75
Isoproterenol acts as a biased agonist of the alpha-1A-adrenoceptor that selectively activates the MAPK/ERK pathway. PLoS One (2015) 0.75
Allosteric communication pipelines in G-protein-coupled receptors. Curr Opin Pharmacol (2016) 0.75
Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders. Schizophr Res Treatment (2016) 0.75
A modification of receptor theory. Br J Pharmacol Chemother (1956) 14.20
Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther (2006) 7.03
Multiple receptors for dopamine. Nature (1979) 5.51
EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. Acta Pharmacol Toxicol (Copenh) (1963) 5.50
Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res (1970) 4.65
Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science (1976) 4.07
Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology (2003) 3.78
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther (2002) 3.67
Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. Arch Int Pharmacodyn Ther (1954) 2.30
The central effects of a novel dopamine agonist. Eur J Pharmacol (1978) 1.73
[Therapeutic method derived from hiberno-therapy in excitation and agitation states]. Ann Med Psychol (Paris) (1952) 1.66
Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology (2006) 1.61
Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology (1999) 1.60
Dopamine partial agonists: a new class of antipsychotic. CNS Drugs (2004) 1.30
Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther (2002) 1.25
Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther (2002) 1.25
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry (2001) 1.22
Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol (2004) 1.19
7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther (1995) 1.17
Dopamine receptors: pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum. Life Sci (1978) 1.17
trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem (1990) 1.14
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord (2006) 1.12
Drugs and receptors. An overview of the current state of knowledge. Drugs (1990) 1.09
Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors. J Pharmacol Exp Ther (1996) 1.06
Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav (1991) 1.05
Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. J Med Chem (1996) 1.02
Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry (1998) 1.01
Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. Eur J Pharmacol (1997) 0.99
Dopamine D2 and D3 receptors inhibit dopamine release. J Pharmacol Exp Ther (1994) 0.98
Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord (2002) 0.97
Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur J Pharmacol (1991) 0.97
Partial dopamine agonists in the treatment of psychosis. J Neural Transm (Vienna) (2002) 0.94
Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. Eur J Pharmacol (1989) 0.94
Schizophrenic symptoms improve with apomorphine. Science (1978) 0.92
Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol (1987) 0.92
Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. J Pharmacol Exp Ther (1992) 0.91
Missing links: mechanisms of protean agonism. Mol Pharmacol (2007) 0.91
Parkinson's disease and D1 dopamine receptors. Curr Opin Investig Drugs (2001) 0.91
Functional selectivity, ligand-directed trafficking, conformation-specific agonism: what's in a name? Mol Interv (2005) 0.88
The use of dopamine agonists in the treatment of schizophrenia. Neuropharmacology (1981) 0.87
Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist. Neuropsychopharmacology (1991) 0.86
Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands. J Med Chem (1989) 0.83
Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine. Arch Gen Psychiatry (1986) 0.82
Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset. Neurosci Lett (1992) 0.82
Effect of apomorphine on schizophrenic symptoms. J Neural Transm (1977) 0.81
Dopamine D1 receptor agonists as antiparkinson drugs. Trends Pharmacol Sci (1998) 0.81
Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands. J Med Chem (1988) 0.80
Pharmacologic properties of (-)-3PPP (preclamol) in man. J Neural Transm Gen Sect (1992) 0.80
Effect of D1 receptor stimulation in normal and MPTP monkeys. Neurosci Lett (1989) 0.80